Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Cypress Pharma cough, cold drugs get FDA approval
Zutripro oral solution and Rezira oral solution, to be marketed by Cypress Pharma’s subsidiary Hawthorn Pharmaceuticals, are indicated for the treatment of cough and other symptoms linked with
Zutripro oral solution and Rezira oral solution, to be marketed by Cypress Pharma’s subsidiary Hawthorn Pharmaceuticals, are indicated for the treatment of cough and other symptoms linked with
The partnership addresses the industry need for IRTsolutions to optimize clinical trial patient randomization, drug supply management and clinical trial status monitoring and reporting. FormsVision was formed to
The company expects to recruit around 880 patients in over 40 hospitals in 9 countries. The aim of this study is to establish Multikine as a first-line standard
The company intends to start shipping upon final authorization by the Drug Enforcement Administration. Divine Skin chairman and CEO Daniel Khesin said since Divine Skin focuses on underserved
Recently, Cortex has received $1,000,000 from Servier for the option to expand its rights for CX1632. As per the terms of the agreement, if Servier exercises the option
Earlier in December 2008, ProStrakan Group, a wholly owned subsidiary of Kyowa Hakko Kirin, has licensed Canadian rights for Abstral to Paladin. Paladin Labs president and CEO Jonathan
Cacciuttolo was MedImmune, Medarex Technical Operations vice president, and was recently president and CEO of PERCIVIA. The company also appointed Ben Machielse and Robert Gailus to the Board
The results of the trial suggested shorter and less severe periods of respiratory depression when treated with MoxDuo IR, compared to morphine or oxycodone. The trial involved approximately
The Phase I clinical trial of VIA-3196 will assess the safety, pharmacokinetics and pharmacodynamics of VIA-3196 in healthy subjects. The company expects to recruit around 72 patients in
RXT 110 has agreed to make payments aggregating to $150,000 over the course of the next four months for an interim license. During the term of the interim